Cited by 1,544Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and ResearchAdvanced Glycation End Products research

Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults

Open access
Selvin, Elizabeth, Steffes, Michael W., Zhu, Hong, Matsushita, Kunihiro, Wagenknecht, Lynne, Pankow, James, Coresh, Josef, Brancati, Frederick L.·2010·New England Journal of Medicine

Abstract

BACKGROUND: Fasting glucose is the standard measure used to diagnose diabetes in the United States. Recently, glycated hemoglobin was also recommended for this purpose. METHODS: We compared the prognostic value of glycated hemoglobin and fasting glucose for identifying adults at risk for diabetes or cardiovascular disease. We measured glycated hemoglobin in whole-blood samples from 11,092 black or white adults who did not have a history of diabetes or cardiovascular disease and who attended the second visit (occurring in the 1990-1992 period) of the Atherosclerosis Risk in Communities (ARIC) study. RESULTS: The glycated hemoglobin value at baseline was associated with newly diagnosed diabetes and cardiovascular outcomes. For glycated hemoglobin values of less than 5.0%, 5.0 to less than 5.5%, 5.5 to less than 6.0%, 6.0 to less than 6.5%, and 6.5% or greater, the multivariable-adjusted hazard ratios (with 95% confidence intervals) for diagnosed diabetes were 0.52 (0.40 to 0.69), 1.00 (reference), 1.86 (1.67 to 2.08), 4.48 (3.92 to 5.13), and 16.47 (14.22 to 19.08), respectively. For coronary heart disease, the hazard ratios were 0.96 (0.74 to 1.24), 1.00 (reference), 1.23 (1.07 to 1.41), 1.78 (1.48 to 2.15), and 1.95 (1.53 to 2.48), respectively. The hazard ratios for stroke were similar. In contrast, glycated hemoglobin and death from any cause were found to have a J-shaped association curve. All these associations remained significant after adjustment for the baseline fasting glucose level. The association between the fasting glucose levels and the risk of cardiovascular disease or death from any cause was not significant in models with adjustment for all covariates as well as glycated hemoglobin. For coronary heart disease, measures of risk discrimination showed significant improvement when glycated hemoglobin was added to models including fasting glucose. CONCLUSIONS: In this community-based population of nondiabetic adults, glycated hemoglobin was similarly associated with a risk of diabetes and more strongly associated with risks of cardiovascular disease and death from any cause as compared with fasting glucose. These data add to the evidence supporting the use of glycated hemoglobin as a diagnostic test for diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa0908359

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose.

    “In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”

    From 2. Diagnosis and Classification of Diabetes: <i>Standards of Care in Diabetes—2024</i> (2024) · cites this paper as [82]

    The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)

    Experimental — accuracy not yet measured
  • In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose.

    “In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (87).”

    From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [87]

    The Abstract Conclusions say that glycated hemoglobin was more strongly associated with cardiovascular disease risk than fasting glucose, but only similarly associated with diabetes risk. The claim overstates the diabetes comparison. (LLM, conf=0.93)

    Experimental — accuracy not yet measured
  • Race did not modify the association between the HbA1c concentration and adverse cardiovascular outcomes or death.

    “However, race did not modify the association between the HbA 1c concentration and adverse cardiovascular outcomes or death (336).”
  • An analysis of 11,092 adults showed that Black individuals had mean HbA1c values 0.4% higher than White individuals.

    “An analysis of 11,092 adults showed that Black individuals had mean HbA 1c values 0.4% higher than White individuals (336).”
  • Careful phenotyping of subjects with oral glucose tolerance testing supports an increase in HbA1c with age, even after removing those with otherwise undiagnosed diabetes and people with impaired glucose tolerance.

    “Careful phenotyping of subjects with OGTT supports an increase in HbA 1c with age, even after removing those with otherwise undiagnosed diabetes and people with impaired glucose tolerance from the study population (336).”

    From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [336]

    The Methods describe fasting-glucose measurements and analyses of diabetes and cardiovascular risk, not phenotyping by oral glucose tolerance test (OGTT). Neither the Results nor the additional passages found for age and impaired glucose tolerance report whether HbA1c rises with age after excluding those groups. The claim cannot be verified from our copy. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L.
Affiliations
  • Johns Hopkins University (US)
  • Wake Forest University Health Sciences (US)
Venue
New England Journal of Medicine
Published
2010-03-04
Volume
362
Issue
9
Pages
800-811
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2096466744
Cited by
1,544
References
48
Citations by year
2026: 52 · 2025: 47 · 2024: 60 · 2023: 65 · 2022: 81 · 2021: 76 · 2020: 85 · 2019: 86 · 2018: 108 · 2017: 95 · 2016: 99 · 2015: 141 · 2014: 112 · 2013: 112 · 2012: 111
FWCI
105.47
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (n01hc55021-47-0-1, 5p60dk079637-02, n01hc55020-39-0-0, n01hc55016-37-0-0, n01hc055022-024, n01hc55019-35-0-1, n01hc55018-38-0-1, n01hc55015-48-0-1)
  • National Heart, Lung, and Blood Institute (N01-HC55022, N01 HC055016, N01-HC-55018, N01 HC 55020, N01 HC 55019, N01 HC055020, N01 HC055018, ­N01-HC55016, N01 HC055022, N01 HC055019, N01‐HC‐55015, N01-HC55021, N01 HC055021, N01 HC055015)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P60 DK-079637, K24-DK62222, K01DK076595, K24DK062222, P30DK079637, R21DK080294)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
Keywords
HbA1c, fasting blood glucose, diabetes diagnosis, cardiovascular risk, coronary artery disease, stroke, all-cause mortality, non-diabetic adults, risk discrimination, Atherosclerosis Risk in Communities Study, HbA1c thresholds, J-shaped association, risk prediction model, diabetes risk prediction, Black and White adults, community-based population
MeSH terms
Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Mortality, Prognosis, Risk, Incidence, Proportional Hazards Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review